ERBB2 and breast cancer: Moreover, in line with a more aggressive biological profile, in the SF group, there was a significantly higher cut-off of ki67 when categorized as ≤20%, and for >20%, an increased frequency of luminal B HER2+ or TN BC and a larger application of primary systemic treatment.